COVID-19 Information

Leib Laboratory


Congratulations to Iara Backes for successfully defending her thesis on February 28th!








Congratulations to Roberto Alers-Velazquez for being accepted to Cornell’s Rising Star Program! A STAR pumpkin carver and know a nationally recognized star postdoc! Read more HERE









Congratulations to Fiona McEnany for being selected as New Hampshire’s Young Person of the Year! First New Hampshire, next The World… [Read more HERE].

Congratulations to Abigail Dutton for passing her qualifying exam on July 23rd, 2021. Congratulations also to her lab for immediately reminding Abigail of her humility in a daring game of volleyball (nice moves, Audra!).








Congratulations to Stacey Ceron for winning the Guarini Diversity Award, 2021. You are so deserving and we are so proud! Read more here.






Congratulations to Stacey Ceron for successfully defending her thesis on May 4th, 2021!










Congratulations to Chaya Patel for successfully defending her thesis on November 10th.

Read all about the the Leib Lab’s efforts on rapid COVID-19 diagnostics.

Research scientist Audra Charron and David Leib, professor of microbiology and immunology at the Geisel School of Medicine, are working with other Dartmouth researchers to validate a new and improved test for the novel coronavirus.


Read more Leib lab news…

Leib Lab Statement


Herpes simplex virus (HSV) is a highly evolved and successful pathogen with a very wide distribution in the human population, close to 100% in some populations. HSV often manages to forge the near-perfect lifelong relationship with us, its human host. Despite the availability of excellent antiviral drugs such as acyclovir and valtrex, HSV is refractory to cure. This is due to the ability of HSV to invade neurons, to translocate to neuronal cell bodies, and establish latent infections therein. Our over-arching interest is to understand how HSV modulates the immune system of the host. This immune-modulation allows HSV to successfully establish latency, and more remarkably, to allow the virus to escape from the immune host to infect other susceptible individuals in the population. Our experimental approach is to use forward and reverse genetics to introduce mutations into the viral genome to generate recombinant viruses. We then use these recombinant viruses in vitro and in vivo to allow the study of viral pathogenesis at the molecular level, and to examine the outcome of the host-pathogen battle.


Recent Publications

Herpes Simplex Virus (HSV)-2 Variation Contributes to Neurovirulence During Neonatal Infection.
Hayes CK, Villota CK, McEnany FB, Ceron S, Awasthi S, Szpara ML, Friedman HM, Leib DA, Longnecker R, Weitzman MD, Akhtar LN
J Infect Dis. 2022 Apr 22; pii: jiac151. doi: 10.1093/infdis/jiac151. Epub 2022 Apr 22.
PMID: 35451492

Herpes Simplex Virus 1 ICP34.5 Alters Mitochondrial Dynamics in Neurons.
Manivanh R, Mehrbach J, Charron AJ, Grassetti A, Ceron S, Taylor SA, Cabrera JR, Gerber S, Leib DA
J Virol. 2020 Jul 1;94(14) pii: e01784-19. doi: 10.1128/JVI.01784-19. Epub 2020 Jul 1.
PMID: 32376626

Trivalent Glycoprotein Subunit Vaccine Prevents Neonatal Herpes Simplex Virus Mortality and Morbidity.
Patel CD, Taylor SA, Mehrbach J, Awasthi S, Friedman HM, Leib DA
J Virol. 2020 May 18;94(11) pii: e02163-19. doi: 10.1128/JVI.02163-19. Epub 2020 May 18.
PMID: 32188735

See more...